JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YEH, B. K.
Right arrow Articles by GOLDBERG, L. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YEH, B. K.
Right arrow Articles by GOLDBERG, L. I.
Journal of Pharmacology And Experimental Therapeutics, Vol. 168, Issue 2, 303-309, 1969
Copyright © 1969 by American Society for Pharmacology and Experimental Therapeutics

ATTENUATION OF DOPAMINE RENAL AND MESENTERIC VASODILATION BY HALOPERIDOL: EVIDENCE FOR A SPECIFIC DOPAMINE RECEPTOR

BILLY K. YEH 1, JOHN L. McNAY 1, and LEON I. GOLDBERG 1

1 Departments of Pharmacology and Medicine (Division of Clinical Pharmacology), Emory University School of Medicine, Atlanta, Georgia

The suggestion that haloperidol is a dopamineblocking agent was investigated by determining the effects of the neuroleptic agent on the renal and mesenteric vasodilation produced in the dog by i.a. injections of dopamine. Doseresponse curves of dopamine, bradykinin and isoproterenol were constructed before and after injection of haloperidol. Prior injections of haloperidol in the renal artery (2 x 10-7 mol) and in the mesenteric artery (2.7 x 10-6 mol) attenuated the effects of dopamine to a significantly greater degree than that of the other agents. By combining 1.4 x 10-7 mol of haloperidol (0.054 mg) with varying doses of the vasodilators, it was possible to demonstrate attenuation of dopamine-induced renal vasodilation without significantly affecting the effects of isoproterenol or bradykinin. The renal vasodilating action of Epinine (N-methyldopamine) was also attenuated by haloperidol. The demonstration that haloperidol selectively attenuates the vasodilating actions of dopamine supports the concept that dopamine acts on a specific receptor in the renal and mesenteric vascular beds.

Submitted on January 18, 1969
Accepted on April 23, 1969




This article has been cited by other articles:


Home page
 Canadian J. AnesthesiaHome page
I. Takamatsu, F. Karasawa, and T. Okuda
Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone: [La dopamine peut mieux preserver la balance en oxygene du myocarde que la dobutamine quand elle est combinee a la milrinone]
Can J Anesth, November 1, 2002; 49(9): 968 - 972.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
I. M. Mitchell, J. C. S. Pollock, and M. P. G. Jamieson
Effects of Dopamine on Liver Blood Flow in Children With Congenital Heart Disease
Ann. Thorac. Surg., December 1, 1995; 60(6): 1741 - 1744.
[Abstract] [Full Text]

Home page
 Arch SurgHome page
I. L. Gordon, R. Wesley, D. H. Wong, M. D. Ingegno, B. Spivak, and S. E. Wilson
Effect of Dopamine on Renal Blood Flow and Cardiac Output
Arch Surg, August 1, 1995; 130(8): 864 - 868.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
S. H. Snyder
Catecholamines in the Brain as Mediators of Amphetamine Psychosis
Arch Gen Psychiatry, August 1, 1972; 27(2): 169 - 179.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics.